Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

Development of Novel Bispecific Anti-Inflammatory and Anti-Angiogenic Therapy for the Treatment of both Retinal Vascular and Inflammatory Diseases

Fernando Correa; Rachel Jacobson; Namrata Prasad; William Ngo; Janine Lu; Carrie Su; Xiaojian Huang; hong liang; D. Victor Perlroth

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5396. doi:

ARVO Annual Meeting Abstract July 2019

Chronic Nonclinical Ocular Toxicity Study of KSI-301 Demonstrates Tolerability after Intravitreal Administration in Cynomolgus Monkeys

John Sinclair; hong liang; zachary antonio; paul miller; avery tolosa; joel naor; leah quarberg; alok sharma; Xiaojian Huang; Janine Lu; William Ngo; dan dang; frances clemo; James N Ver Hoeve; T. Michael Nork; D. Victor Perlroth

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):126. doi:

ARVO Annual Meeting Abstract July 2018

KSI-301: An anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases

hong liang; Xiaojian Huang; William Ngo; Dan Dang; Janine Lu; Rachel DeVay Jacobson; Ons Harrabi; D. Victor Perlroth

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):211. doi:

ARVO Annual Meeting Abstract July 2018

Development and characterization of a prototype antibody biopolymer conjugate targeting the complement system

Rachel DeVay Jacobson; Dan Dang; William Ngo; Janine Lu; Amy Duguay; Ons Harrabi; Xiaojian Huang; hong liang; D. Victor Perlroth

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):219. doi:

ARVO Annual Meeting Abstract July 2018

Development of potent dual action biopharmaceuticals for the treatment and prevention of neovascular retinal diseases

Fernando Correa; Rachel DeVay Jacobson; hong liang; Namrata Prasad; Xiaojian Huang; William Ngo; Dan Dang; Janine Lu; D. Victor Perlroth

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5312. doi:

Advertisement